New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

We are navigating political interference, institutional instability, and growing uncertainty across the cancer research ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

Immunotherapy let some cancer patients with mismatch repair deficient tumors completely avoid surgery, chemo and radiation, a ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

A new, small cancer study may give hope to patients with solid tumors in the stomach, esophagus or rectum. The standard ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

The session follows the American Association for Cancer Research's prior call to action against executive orders that would ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...